XBIvsLFSCETF Comparison
VS
State Street SPDR S&P Biotech ETF (XBI) belongs to the US Health Care segment. F/m Emerald Life Sciences Innovation ETF (LFSC) is part of the Life Sciences segment. XBI's top 3 sector exposures are Healthcare and Finance. In contrast, LFSC's top sector exposures are Healthcare and Sovereign. XBI is less expensive with a Total Expense Ratio (TER) of 0.35%, versus 0.79% for LFSC. XBI is up 24.76% year-to-date (YTD) with +$510M in YTD flows. LFSC performs worse with 23.23% YTD performance, and +$8M in YTD flows. Run a side-by-side ETF comparison of XBI and LFSC below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
XBI vs LFSC performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 07/22/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | XBI LFSC | +4.20%+4.17% | +10.82%+20.39% | +24.76%+23.23% | +76.10%+82.30% | +83.33%n/a | +19.73%n/a |
| Flows | XBI LFSC | +$459M+$2M | +$279M+$3M | +$510M+$8M | +$1.45B+$17M | -$425M- | +$1.59B- |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | XBI LFSC | +30.98%+26.23% | +26.78%+26.91% | +27.91%n/a | +32.90%n/a |
| Max drawdown | XBI LFSC | -8.13%-6.53% | -9.66%-16.25% | -32.94%n/a | -54.07%n/a |
| Max drawdown duration | XBI LFSC | 13d20d | 76d168d | 331dn/a | 1685dn/a |
Trading data
XBI | LFSC | |
Last sale 7/24/2026 at 1:30 PM | $150.48 | $45.10 |
| Previous close 07/23/2026 | $152.23 | $45.46 |
| Consolidated volume 07/23/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of June 30, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
LFSC
is actively managed and doesn’t replicate an indexXBI | LFSC | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 7/24/2026 at 1:30 PM
Live
Closed
XBI | LFSC | |
|---|---|---|
| Last price | $150.48 | $45.10 |
| 1D performance | -1.15% | -0.79% |
| AuM | $10.24 B | $123.48 M |
| E/R | 0.35% | 0.79% |
Characteristics
XBI | LFSC | |
|---|---|---|
| Management strategy | Passive | Active |
| Provider | State Street Investment Management | Emerald Group |
| Benchmark | S&P Biotechnology Select Industry Index | - |
| N° of holdings | 150 | 40 |
| Asset class | Equities | - |
| Trailing 12m distribution yield | Join | Join |
| Inception date | January 31, 2006 | October 31, 2024 |
| ESG | No | No |
Advertisement
Exposure
Countries
XBI
USA
95.06%
Other
4.94%
LFSC
USA
90.9%
United Kingdom
7.04%
Other
2.06%
Sectors
XBI
Healthcare
99.03%
Other
0.97%
LFSC
Healthcare
98.03%
Other
1.97%
Advertisement
Diversification
XBI
Total weight of top 15 holdings out of 15
19.19%
LFSC
Total weight of top 15 holdings out of 15
73.24%
Top 15 holdings
Data as of June 30, 2026
XBI
Apogee Therapeutics, Inc.
1.48%
Moderna, Inc.
1.41%
Twist Bioscience Corp.
1.40%
Oruka Therapeutics, Inc.
1.37%
Kymera Therapeutics, Inc.
1.35%
Viking Therapeutics, Inc.
1.30%
Praxis Precision Medicines, Inc.
1.29%
Erasca, Inc.
1.27%
Revolution Medicines, Inc.
1.20%
Rhythm Pharmaceuticals, Inc.
1.20%
CG Oncology, Inc.
1.20%
SELLAS Life Sciences Group, Inc.
1.19%
Vaxcyte, Inc.
1.18%
Dianthus Therapeutics, Inc.
1.18%
Cytokinetics, Inc.
1.17%
LFSC
Travere Therapeutics, Inc.
8.37%
Cogent Biosciences, Inc.
7.18%
LivaNova Plc
7.04%
Spyre Therapeutics, Inc.
6.71%
Guardant Health, Inc.
5.56%
Corcept Therapeutics, Inc.
5.27%
Mirum Pharmaceuticals, Inc.
5.25%
BillionToOne, Inc.
4.25%
Cytokinetics, Inc.
4.13%
Veradermics, Inc.
3.76%
United Therapeutics Corp.
3.55%
Trevi Therapeutics, Inc.
3.50%
Savara, Inc.
3.20%
Dianthus Therapeutics, Inc.
2.77%
Nektar Therapeutics
2.70%
Frequently asked questions about XBI and LFSC
How have the XBI and LFSC ETFs performed in 2026?
As of July 22, 2026, XBI is up 24.76% year-to-date (YTD), while LFSC has returned 23.23%. That puts XBI better performer ahead so far this year.
Which ETF is attracting more investor money: XBI or LFSC?
Year-to-date, the XBI ETF saw +$510M in flows, compared to +$8M for LFSC.
Which ETF is more volatile: XBI or LFSC?
Over the past year, XBI had a volatility of 26.78%, while LFSC experienced 26.91%.
Which ETF is bigger: XBI or LFSC?
As of July 22, 2026, XBI holds $10.24 B in assets under management (AUM), while LFSC manages $123.48 M.
What sectors do the XBI and LFSC ETFs invest in?
XBI leans toward sectors like Healthcare. Meanwhile, LFSC focuses on Healthcare.
What are the top holdings of the XBI ETF and LFSC ETF?
XBI top holdings include Apogee Therapeutics, Inc., Moderna, Inc. and Twist Bioscience Corp.. LFSC holds in its top three: Travere Therapeutics, Inc., Cogent Biosciences, Inc. and LivaNova Plc.
Which ETF is more diversified: XBI or LFSC?
XBI holds 153 securities with 19.19% of its assets in the top 15. LFSC has 40 securities and a top 15 weight of 73.24%.
Advertisement
Latest news about XBI & LFSC
Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities
September 18, 2025
XBI
Are Biotechnology ETFs In the Midst of a Comeback?
August 20, 2025
XBI
Two biotech ETFs to watch for the rest of 2022 and beyond
September 13, 2022
XBI
Biotech ETFs – Investing in Health Innovation
July 21, 2022
XBI
Advertisement
Advertisement
